Sign in to continue:

Saturday, August 1st, 2026

Pelican Acquisition II Corp Faces Going Concern Doubts After $86M SPAC IPO – Audited Financial Statement Insights

Pelican Acquisition II Corp: Key Details from Audited Financial Statement and IPO

Pelican Acquisition II Corporation (NASDAQ: PLCIU), a recently established blank check company incorporated in the Cayman Islands, has published its audited financial statement as of July 27, 2026. The report, prepared by Simon & Edward, LLP, offers investors a comprehensive snapshot of the company’s financial position, business model, and future prospects. Below is a detailed analysis of the financial statement and critical disclosures for current and prospective shareholders.

Key Highlights from the Financial Statement

  • IPO and Capital Structure: On July 27, 2026, Pelican Acquisition II Corp completed its initial public offering (IPO), raising \$86,250,000 through the sale of 8,625,000 units at \$10.00 per unit. Each unit comprises one ordinary share and one right, with each right converting into one-tenth of an ordinary share upon the consummation of a business combination. Simultaneously, 420,250 private units were sold to the Sponsor and EarlyBirdCapital (EBC) for \$4,202,500, bringing total cash held in trust to \$87,112,500.
  • Balance Sheet Strength: As of July 27, 2026, total assets stood at \$88,078,218, with cash and cash equivalents of \$641,640 and prepaid expenses of \$89,078. Liabilities were minimal, at just \$89,599, mostly accounts payable and accrued expenses.
  • Redemption Features: 8,625,000 ordinary shares are subject to possible redemption at \$10.10 per share, for a total possible redemption value of \$87,112,500. The shares are classified as temporary equity due to the redemption feature, which is a typical SPAC (Special Purpose Acquisition Company) structure.
  • Shareholder Equity: After accounting for possible redemptions and transaction costs, shareholder equity amounts to \$5,440,338.

Critical Shareholder Information & Potential Price-Sensitive Issues

  • Going Concern Warning:

    • The independent auditor has issued a substantial doubt about the company’s ability to continue as a going concern.
    • If a business combination is not completed within 21 months of the IPO (by April 27, 2028), or an extended date approved by shareholders, the company will be required to liquidate, returning funds to public shareholders. This is a key risk factor that investors must monitor closely, as failure to secure a deal would result in the winding up of the company.
  • Redemption Rights and Shareholder Decisions:

    • Public shareholders have the right to redeem their shares for a pro-rata portion of the trust account (initially \$10.10 per share), either in connection with a shareholder vote on a business combination or via a tender offer.
    • If the company seeks an extension to the business combination deadline, shareholders will again have the right to redeem for cash.
  • Founder and Insider Shares:

    • Founder shares (2,875,000) and EBC founder shares (200,000) are subject to transfer restrictions and do not have redemption rights. These shares are subject to a 180-day lock-up post-business combination for founders, and 30 days for holders of private units.
  • Contingent Liabilities and Sponsor Support:

    • The sponsor has agreed to cover claims by vendors or target companies if such claims reduce the trust funds below \$10.10 per public share (except in certain circumstances). This provides an additional layer of security for public shareholders.
  • Potential Dilution and Conversion Features:

    • Up to \$1.5 million in working capital loans from the sponsor, officers, or directors may be converted into private units at \$10.00 per unit, potentially diluting public shareholders if exercised.
    • Each right entitles the holder to 1/10th of an ordinary share upon business combination, which could increase the ordinary share count and affect share price post-combination.
  • Transaction Costs and Underwriting Agreements:

    • IPO transaction costs totaled \$2,444,638, including \$1,725,000 in cash underwriting commissions and other offering expenses.
    • EBC is entitled to additional fees upon successful business combination, including a 3.5% service fee of IPO gross proceeds and a 1% finder’s fee under certain conditions.
    • EBC holds rights of first refusal for future equity-linked financings and potential future public offerings, potentially impacting future capital raises or mergers.
  • Macroeconomic and Geopolitical Risks:

    • The company highlights potential risks from global conflicts, U.S.-China tensions, and changes in trade policies, all of which could impact the ability to consummate a business combination or raise financing.

Other Important Disclosures

  • Accounting Policies: The company is an Emerging Growth Company and may take advantage of reduced reporting obligations under the JOBS Act, which could affect transparency and comparability with other public companies.
  • No Cayman Islands Corporate Tax: The company is not subject to income tax in the Cayman Islands.
  • Segment Reporting: The company has only one reportable segment, focused solely on completing a business combination.
  • No Subsequent Events: No significant events have occurred post-balance sheet date through the issuance date of the financial statement.

Investor Takeaways

  • Pelican Acquisition II Corporation is in its early stages, with no operating business as of July 2026. The company’s future and share value are entirely dependent on its ability to identify and consummate a business combination before April 27, 2028.
  • The going concern warning and the risk of liquidation are material and could be price sensitive, particularly if the company struggles to find a suitable acquisition target.
  • Shareholders should monitor updates regarding business combination progress, redemption rights, potential extensions, and any changes in macroeconomic or political conditions that could impact deal-making.
  • Any announcements about a target business or failure to secure a business combination within the prescribed timeframe could significantly impact the share price.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities. Investors should conduct their own due diligence and consult with their financial advisor before making investment decisions. The author and publisher are not responsible for any losses arising from reliance on this information.

View Pelican Acquisition II Corp Historical chart here



TScan Therapeutics, Inc. 2025 Annual Report: Business Overview, Strategy, Risks, and Pipeline Highlights

TScan Therapeutics, Inc. 2025 Annual Report — Key Investor I...

FONAR Corporation 8-K Filing Details Proposed Merger, Company Information, and SEC Compliance – May 21, 2026

FONAR Corporation Issues Supplemental Disclosures Amid Merge...